Literature DB >> 1682022

Expression of the immediate early gene c-fos in basal ganglia: induction by dopaminergic drugs.

H A Robertson1, M L Paul, R Moratalla, A M Graybiel.   

Abstract

Expression of the immediate early gene c-fos is increased in mammalian neurons by a number of stimuli and the usefulness of this gene as a marker of neuronal activation has been demonstrated in several systems. Directly-acting dopamine agonists of the D1-type (SKF 38393, CY 208-243) and indirectly-acting dopamine agonists (amphetamine, cocaine) all produce a rapid and transient increase in Fos protein levels in varying patterns in striatum and cerebral cortex. Directly-acting dopamine agonists only produce c-fos activation in denervated (supersensitive) striatum whereas cocaine and amphetamine activate c-fos in striatum in naive animals. Remarkably, D2 selective antagonists such as haloperidol, albeit in high doses, also activate c-fos expression. Activation of c-fos and other immediate early genes may play a part in the development of such long-term dopamine-related effects as dyskinetic movements and addiction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682022     DOI: 10.1017/s0317167100032480

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  19 in total

1.  Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue.

Authors:  S Basu; P S Dasgupta
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 2.  Dopamine receptor genes: new tools for molecular psychiatry.

Authors:  H B Niznik; H H Van Tol
Journal:  J Psychiatry Neurosci       Date:  1992-10       Impact factor: 6.186

3.  Modulation of Postnatal Neurogenesis by Perinatal Asphyxia: Effect of D1 and D2 Dopamine Receptor Agonists.

Authors:  A Tapia-Bustos; R Perez-Lobos; V Vío; C Lespay-Rebolledo; E Palacios; A Chiti-Morales; D Bustamante; M Herrera-Marschitz; P Morales
Journal:  Neurotox Res       Date:  2016-09-16       Impact factor: 3.911

4.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

5.  Enhanced behavioral response to repeated-dose cocaine in adolescent rats.

Authors:  Joseph M Caster; Q David Walker; Cynthia M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  Selective activation of D1 dopamine receptors impairs sensorimotor gating in Long-Evans rats.

Authors:  Laura J Mosher; Roberto Frau; Alessandra Pardu; Romina Pes; Paola Devoto; Marco Bortolato
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

7.  Transsynaptic induction of c-fos in basal forebrain, diencephalic and midbrain neurons following AMPA-induced activation of the dorsal and ventral striatum.

Authors:  K J Page; B J Everitt
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  High- and low-frequency repetitive transcranial magnetic stimulation differentially activates c-Fos and zif268 protein expression in the rat brain.

Authors:  Selcen Aydin-Abidin; Jörn Trippe; Klaus Funke; Ulf T Eysel; Alia Benali
Journal:  Exp Brain Res       Date:  2008-04-02       Impact factor: 1.972

9.  Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling.

Authors:  Jianhong Li; Yin Guo; Frederick A Schroeder; Rachael M Youngs; Thomas W Schmidt; Craig Ferris; Christine Konradi; Schahram Akbarian
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

10.  5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen.

Authors:  Lara A Pockros; Nathan S Pentkowski; Sineadh M Conway; Teresa E Ullman; Kimberly R Zwick; Janet L Neisewander
Journal:  Synapse       Date:  2012-09-11       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.